You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

By the time of diagnosis, your COPD patients may already have lost 50% of their lung function 1

As a healthcare professional managing a busy caseload of symptomatic COPD patients every day, watching this video could help you make informed treatment decisions for your COPD patients and optimise their treatment.

There is no time to waste for lung function improvement. Wouldn’t you want to give your COPD patients a more effective treatment vs. tiotropium/olodaterol if there was a comparable safety profile?

Watch our video, and see why you should start with Anoro Ellipta instead of tiotropium* and tiotroprium/olodaterol** when making the decision to start initial maintenance therapy for your symptomatic patients with COPD. 2 5 6

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/anoro-ellipta-h2h-vs-imt-options-animated-infographic.mp4

Download the infographic to identify the patient type who could benefit from starting maintenance therapy for their COPD symptoms, and review the efficacy and safety data for Anoro Ellipta to make an informed treatment decision.

ANORO ELLIPTA is indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD). 4

Footnotes

Details of the blinding process for all tiotropium comparator studies discussed in this web page can be found on page 474 in Decramer M et al. Lancet Respir Med 2014 and page 2190 in Maleki-Yazdi M et al. Adv Ther 2016 2 5

Anoro Safety Information: Contraindicated in patients with hypersensitivity to the active substances or to any of the excipients, or in patients with severe milk-protein allergy. Caution advised in patients with severe cardiovascular disease, urinary retention, narrow angle glaucoma, convulsive disorders, thyrotoxicosis, hypokalaemia, hyperglycaemia, severe hepatic impairment. Do not use in patients with asthma. Not indicated for acute episodes of bronchospasm. Common adverse reactions include urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation, dry mouth.4

*Up to 2.4x greater improvement in lung function vs. tiotropium (pooled post hoc analysis) (252mL vs. 107mL; p<0.001)** 2 3

Number of subjects with analysable data at Day 169 based on a pooled post hoc analysis of three 24-week studies 2 3 5

**Trough FEV1 improved by 180mL from baseline for Anoro Ellipta (n=225) vs. 128mL for tiotroprium over an 8-week treatment period in the ITT population; treatment difference 52mL (95% Cl: 28, 77; p<0.001)6

Reference:

  1. Sutherland ER, Cherniack RM. N Engl J Med 2004; 350:2689–2697.
  2. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199.
  3. GSK data on file; RF/UCV/0112/15(1).
  4. Anoro Ellipta SmPC, 2020.
  5. Feldman GJ et al. Adv Ther 2017; 34:2518–2533.
  6. Decramer M et al. Lancet Respir Med 2014; 2:472–486.
Innoviva logo

© 2018 GlaxoSmithKline Group of Companies. Anoro and Ellipta are trademarks of the GlaxoSmithKline group of companies.
Anoro Ellipta was developed in collaboration with Innoviva.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.